$152.72-1.58 (-1.02%)
Globe Life Inc., through its subsidiaries, provides various life and supplemental health insurance products to lower middle- and middle-income families in the United States.
Globe Life Inc. in the Financial Services sector is trading at $152.72. The stock is currently near its 52-week high of $155.08, remaining 9.8% above its 200-day moving average. Technical signals show neutral RSI of 68 and bullish MACD crossover, explaining why GL maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Globe Life Inc., through its subsidiaries, provides various life and supplemental health insurance products to lower middle- and middle-income families in the United States. It operates in three segments: Life Insurance, Supplemental Health Insurance...
In April 2026, Globe Life Inc. reported first-quarter revenue of US$1,559.62 million and net income of US$270.53 million, while raising its full-year 2026 earnings guidance to US$15.40–US$15.90 per share and continuing to retire shares through its long-running buyback program. A key insight is that management linked the upgraded outlook to strong health premium growth, AI-driven efficiency efforts, and accelerated share repurchases, underscoring the importance of both operational performance...
A Relative Strength Rating upgrade for Voya Financial shows improving technical performance. Will it continue?
Insurance holding company Globe Life (NYSE:GL) met Wall Street’s revenue expectations in Q1 CY2026, with sales up 5.4% year on year to $1.56 billion. Its non-GAAP profit of $3.43 per share was 1.3% below analysts’ consensus estimates.
Globe Life Inc (GL) reports a 12% increase in net operating income per share and outlines AI-driven strategies to enhance efficiency and growth.
Globe Life (NYSE:GL) reported higher first-quarter earnings and updated its 2026 outlook, as management pointed to continued underwriting profitability, strong health sales momentum, and an accelerated share repurchase pace driven by excess cash flow and what executives described as favorable market